2010/06/29 by Farshid Dayyani, Carol J. Etzel, Mei Liu +3 · 3 citations
Dentistry · Medicine · #Cancer #Head and Neck Cancer Studies #Head and Neck Surgical Oncology #Head and neck #Head and neck cancer #Head and neck squamous-cell carcinoma #Head and neck surgery #Human papillomavirus #Internal medicine #Medicine #Meta-analysis #Oncology #Oral Health Pathology and Treatment #Otorhinolaryngology #Squamous cell cancer #Surgery
paper · pdf · doi:10.1186/1758-3284-2-15
openalex publication_date 2010/06/29 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
BACKGROUND: HPV is important in a subset of HNSCC. Our meta-analysis determined the clinical characteristics of HPV-related HNSCC. METHOD: Pubmed search terms "HPV" and "HNSCC" were used to identify 34 studies since 1980. We obtained pooled adjusted odds ratio (OR) or hazard ratio (HR) using random or fixed-effects model and compared OS depicted in forest plot. RESULTS: A total of 5681 patients were included. The prevalence of HPV+ tumors was 22%, with 86.7% of HPV16+ genotype. The OR for HNSCC in HPV16+ patients was 4.44 (95% CI = 2.87-6.02). HPV status was associated with p16 expression (adj OR = 3.00; 0.90-9.70), and HPV+ tumors were less likely to harbor p53 mutations (adj OR = 0.21; 0.04-0.38). The HR for death in HPV+ patients was 0.42 (0.27-0.57). HPV+ HNSCC also had a better response to therapy. CONCLUSION: HPV+ HNSCC are established as a separate biologic entity. Prospective trials are needed to establish the optimal therapy for HPV+ HNSCC.